Eli Lilly/$LLY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Health
Primary listing
NYSE
Employees
47,000
Headquarters
Website
Eli Lilly Metrics
BasicAdvanced
$575B
41.91
$15.29
0.44
$5.60
0.94%
Price and volume
Market cap
$575B
Beta
0.44
52-week high
$972.53
52-week low
$633.20
Average daily volume
4.2M
Dividend rate
$5.60
Financial strength
Total debt to equity
243.609
Interest coverage (TTM)
25.31%
Profitability
EBITDA (TTM)
24,777.9
Gross margin (TTM)
82.64%
Net profit margin (TTM)
25.91%
Operating margin (TTM)
43.00%
Effective tax rate (TTM)
18.15%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Valuation
Price to earnings (TTM)
41.906
Price to revenue (TTM)
10.814
Price to book
38.52
Price to tangible book (TTM)
152.52
Dividend yield (TTM)
0.87%
Forward dividend yield
0.94%
Growth
Revenue change (TTM)
36.83%
Earnings per share change (TTM)
88.31%
3-year revenue growth (CAGR)
22.36%
10-year revenue growth (CAGR)
10.50%
3-year earnings per share growth (CAGR)
34.61%
10-year earnings per share growth (CAGR)
23.01%
3-year dividend per share growth (CAGR)
15.23%
10-year dividend per share growth (CAGR)
10.96%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Bulls say / Bears say
Eli Lilly’s diabetes and obesity division is projected to grow 41% in 2025—well above Novo Nordisk’s 25%—underscoring its leading position in the incretin market (Reuters).
The company’s 2025 guidance of $58 billion to $61 billion in revenue and adjusted EPS of $22.50 to $24.00 is largely above Wall Street estimates, reflecting confidence in sustained growth from key therapies (Reuters).
Recent positive trial results for next-generation obesity drugs like retatrutide and orforglipron have significantly bolstered investor outlook and driven Lilly’s valuation above peers (Reuters).
Lilly forecasted weaker-than-expected Q4 sales for its GLP-1 drugs, with Mounjaro and Zepbound missing analyst targets and sparking an over 8% stock decline after predicting $3.5 billion in Mounjaro sales versus $5.35 billion expected and $1.9 billion in Zepbound sales versus $2.08 billion forecast (Reuters).
A Mercer survey found that 51% of large U.S. employers plan to cut health benefits in 2026 due to surging costs from specialty and weight-loss drugs like Zepbound and Mounjaro, potentially limiting coverage and reimbursement for Lilly’s high-priced therapies (Reuters).
Intensifying competition from other obesity treatments—such as Roche’s orforglipron and emerging triple-agonists—and concerns around lower perceived efficacy may pressure Lilly’s market share and valuation despite its pipeline strength (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 24 Jul 2025.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Aug15
Eli Lilly
Dividend·Ex-dividend
Sept10
Eli Lilly
Dividend·Payment
$1.50Per share
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $575B as of August 11, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 41.91 as of August 11, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of August 11, 2025, the dividend rate is $5.6 and the yield is 0.94%. Eli Lilly has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment is scheduled for September 10, 2025.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.